SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut.

BACKGROUND: Infection fatality rate and infection hospitalization rate, defined as the proportion of deaths and hospitalizations, respectively, of the total infected individuals, can estimate the actual toll of coronavirus disease 2019 (COVID-19) on a community, as the denominator is ideally based on a representative sample of a population, which captures the full spectrum of illness, including asymptomatic and untested individuals. OBJECTIVE: To determine the COVID-19 infection hospitalization rate and infection fatality rate among the non-congregate population in Connecticut between March 1 and June 1, 2020. METHODS: The infection hospitalization rate and infection fatality rate were calculated for adults residing in non-congregate settings in Connecticut prior to June 2020. Individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were estimated using the seroprevalence estimates from the recently conducted Post-Infection Prevalence study. Information on total hospitalizations and deaths was obtained from the Connecticut Hospital Association and the Connecticut Department of Public Health, respectively. RESULTS: Prior to June 1, 2020, nearly 113,515 (90% confidence interval [CI] 56,758-170,273) individuals were estimated to have SARS-CoV-2 antibodies, and there were 7792 hospitalizations and 1079 deaths among the non-congregate population. The overall COVID-19 infection hospitalization rate and infection fatality rate were estimated to be 6.86% (90% CI, 4.58%-13.72%) and 0.95% (90% CI, 0.63%-1.90%), respectively, and there was variation in these rate estimates across subgroups; older people, men, non-Hispanic Black people, and those belonging to 2 of the counties had a higher burden of adverse outcomes, although the differences between most subgroups were not statistically significant. CONCLUSIONS: Using representative seroprevalence estimates, the overall COVID-19 infection hospitalization rate and infection fatality rate were estimated to be 6.86% and 0.95%, respectively, among community residents in Connecticut.

Preparation of cyflumetofen nanocapsules and study on the controlled release performance and its field efficacy.

BACKGROUND: In this study, 5% cyflumetofen nanocapsules were prepared by interfacial polymerization with isophorone diisocyanate and polyethylene glycol as the reaction monomer, and tristyrylphenol polyoxyethylene ether (601-P) as the emulsifier. The physical, chemical and sustained release properties of cyflumetofen nanocapsules were characterized using scanning electron microscopy, field emission scanning electron microscopy, laser particle size analysis, Fourier transform infrared spectroscopy, contact angles testing and high-performance liquid chromatography. RESULTS: The results indicated that cyflumetofen nanocapsules were spherical, with an average particle size of 100 nm, and an encapsulation efficiency and loading rate of 86% and 32%, respectively. The thermal and cold storage stabilities of cyflumetofen nanocapsules were good. Under high temperature, lower pH or a high core-wall ratio, nanoparticle release is faster. The field efficacy experiment indicated that the efficacy of cyflumetofen nanocapsules against Panonychus citri reached 97%, 30 days after spraying, significantly greater than that of a 20% cyflumetofen suspension. CONCLUSION: It is important to increase the stability, lengthen the release period and improve the efficacy of cyflumetofen in cyflumetofen nanocapsules. © 2018 Society of Chemical Industry.